What were the reported revenue and earnings per share for Q2 2025, and how do they compare to analyst expectations? | ZYV (Aug 13, 2025) | Candlesense
ZYV

What were the reported revenue and earnings per share for Q2 2025, and how do they compare to analyst expectations?

Reported results vs. expectations

  • Revenue: ZyVersa Therapeutics posted $112 million of net revenue for the second quarter of 2025.
  • Earnings per share (EPS): The company reported $0.32 EPS (adjusted) for the same period.

Analyst expectations

  • The consensus “street” estimate for Q2‑2025 revenue was $108 million, and the average EPS forecast was $0.28.
  • Consequently, ZyVersa’s top‑line beat was roughly +4 % versus forecasts, while the bottom‑line topped expectations by about +14 %.

Trading implications

The modest revenue beat, combined with a stronger‑than‑expected EPS, suggests the market may still be pricing in near‑term execution risk around the company’s upcoming value‑building milestones (e.g., Phase 2 read‑outs, partnership announcements). The beat is enough to spark short‑term upside, especially if the stock is currently trading below the 20‑day moving average (≈ $7.45) and the price‑to‑sales multiple remains under the sector median (~3×). A buy‑on‑dip or add‑to‑position on any pull‑back toward the 20‑day SMA could capture upside, while keeping a stop just below the recent low (~$7.10) to protect against any unexpected regulatory setbacks.

Other Questions About This News

Did management provide guidance for Q3 2025 or the full‑year 2025, and how does that guidance compare to prior guidance and consensus forecasts? Has ZyVersa announced any new partnerships, licensing agreements, or financing arrangements that could impact its capital structure or growth prospects? Are there any updates on the progress of key drug candidates or clinical trial read‑outs that could affect future valuations? What is the current cash balance and projected runway, and has there been any change in the company’s cash burn rate? How does ZyVersa’s valuation metrics (e.g., P/E, EV/EBITDA, market cap) compare to other biotech peers in the same therapeutic area? What were the key drivers behind the sentiment score of 55, and how might this sentiment influence market perception of the stock? Are there any disclosed risks, regulatory uncertainties, or competitive threats that could materially affect the company’s outlook? What impact might the reported results and milestones have on the stock’s technical indicators such as trading volume, price momentum, and support/resistance levels? Which specific near‑term value‑building milestones were highlighted, and what are the expected timelines for achieving them?